
News|Articles|February 19, 2026
From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle
Author(s)CoverMyMeds
Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.
What you’ll learn:
- Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively.
- Learn how data-driven insights and affordability solutions can help biopharma support providers and pharmacists at every stage.
- Understand the strategic role of lifecycle planning in improving medication access, reducing industry fragmentation and enhancing patient outcomes.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
2
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
3
Pharma Funding Roundup: Excalipoint Therapeutics Completes $68.7 Million Seed Finance Round, Crossbow Therapeutics Raises $77 Million in Series B Financing
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5